Cargando…

Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages

BACKGROUND: Radiation therapy is considered important for the treatment of intranasal tumors in dogs and is believed to be essential for prolonging their survival. AIM: To investigate the contribution of clinical staging to improve outcomes of megavoltage radiotherapy for canine intranasal tumors. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Iseri, Toshie, Horikirizono, Hiro, Abe, Momoko, Itoh, Harumichi, Sunahara, Hiroshi, Nemoto, Yuki, Itamoto, Kazuhito, Tani, Kenji, Nakaichi, Munekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculty of Veterinary Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270932/
https://www.ncbi.nlm.nih.gov/pubmed/35821780
http://dx.doi.org/10.5455/OVJ.2022.v12.i3.12
_version_ 1784744571252506624
author Iseri, Toshie
Horikirizono, Hiro
Abe, Momoko
Itoh, Harumichi
Sunahara, Hiroshi
Nemoto, Yuki
Itamoto, Kazuhito
Tani, Kenji
Nakaichi, Munekazu
author_facet Iseri, Toshie
Horikirizono, Hiro
Abe, Momoko
Itoh, Harumichi
Sunahara, Hiroshi
Nemoto, Yuki
Itamoto, Kazuhito
Tani, Kenji
Nakaichi, Munekazu
author_sort Iseri, Toshie
collection PubMed
description BACKGROUND: Radiation therapy is considered important for the treatment of intranasal tumors in dogs and is believed to be essential for prolonging their survival. AIM: To investigate the contribution of clinical staging to improve outcomes of megavoltage radiotherapy for canine intranasal tumors. METHODS: A total of 123 dogs with intranasal tumors were included in the study. Forty-eight dogs received orthovoltage radiotherapy after cytoreductive surgery (Group I), 21 received orthovoltage radiotherapy without surgery (Group II), and 54 received megavoltage radiotherapy without surgery (Group III). All cases in each group were classified into clinical stages 1–4, and the median survival time (MST) was compared for each stage in all groups. RESULTS: The overall MST was not significantly difference among Group I (325 days), Group II (317 days), and Group III (488 days); however, Group III was prolonged than Groups I and II. The MSTs for stages 1, 2, 3, and 4 were 597, 361, 267, and 325 days in Group I; 633, 260, 233, and 329 days in Group II; and 931, 860, 368, and 176 days in Group III, respectively. The MST for stage 2 cases in Group III was significantly prolonged when compared with that in Groups I and II; no significant difference was observed at other stages; however, the MST in Group III was longer in stage 1. These results showed that megavoltage radiotherapy prolonged the MST in dogs with intranasal tumors when compared to orthovoltage radiation with or without cytoreductive surgery, and that improvements in MST at stage 2 contributed significantly to this. CONCLUSION: The improvement in the MST in dogs with stages 1 and 2 intranasal tumors highlights the importance of starting megavoltage radiotherapy in the early stages.
format Online
Article
Text
id pubmed-9270932
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Faculty of Veterinary Medicine
record_format MEDLINE/PubMed
spelling pubmed-92709322022-07-11 Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages Iseri, Toshie Horikirizono, Hiro Abe, Momoko Itoh, Harumichi Sunahara, Hiroshi Nemoto, Yuki Itamoto, Kazuhito Tani, Kenji Nakaichi, Munekazu Open Vet J Original Research BACKGROUND: Radiation therapy is considered important for the treatment of intranasal tumors in dogs and is believed to be essential for prolonging their survival. AIM: To investigate the contribution of clinical staging to improve outcomes of megavoltage radiotherapy for canine intranasal tumors. METHODS: A total of 123 dogs with intranasal tumors were included in the study. Forty-eight dogs received orthovoltage radiotherapy after cytoreductive surgery (Group I), 21 received orthovoltage radiotherapy without surgery (Group II), and 54 received megavoltage radiotherapy without surgery (Group III). All cases in each group were classified into clinical stages 1–4, and the median survival time (MST) was compared for each stage in all groups. RESULTS: The overall MST was not significantly difference among Group I (325 days), Group II (317 days), and Group III (488 days); however, Group III was prolonged than Groups I and II. The MSTs for stages 1, 2, 3, and 4 were 597, 361, 267, and 325 days in Group I; 633, 260, 233, and 329 days in Group II; and 931, 860, 368, and 176 days in Group III, respectively. The MST for stage 2 cases in Group III was significantly prolonged when compared with that in Groups I and II; no significant difference was observed at other stages; however, the MST in Group III was longer in stage 1. These results showed that megavoltage radiotherapy prolonged the MST in dogs with intranasal tumors when compared to orthovoltage radiation with or without cytoreductive surgery, and that improvements in MST at stage 2 contributed significantly to this. CONCLUSION: The improvement in the MST in dogs with stages 1 and 2 intranasal tumors highlights the importance of starting megavoltage radiotherapy in the early stages. Faculty of Veterinary Medicine 2022 2022-06-07 /pmc/articles/PMC9270932/ /pubmed/35821780 http://dx.doi.org/10.5455/OVJ.2022.v12.i3.12 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Iseri, Toshie
Horikirizono, Hiro
Abe, Momoko
Itoh, Harumichi
Sunahara, Hiroshi
Nemoto, Yuki
Itamoto, Kazuhito
Tani, Kenji
Nakaichi, Munekazu
Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title_full Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title_fullStr Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title_full_unstemmed Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title_short Outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
title_sort outcomes of megavoltage radiotherapy for canine intranasal tumors and its relationship to clinical stages
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270932/
https://www.ncbi.nlm.nih.gov/pubmed/35821780
http://dx.doi.org/10.5455/OVJ.2022.v12.i3.12
work_keys_str_mv AT iseritoshie outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT horikirizonohiro outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT abemomoko outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT itohharumichi outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT sunaharahiroshi outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT nemotoyuki outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT itamotokazuhito outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT tanikenji outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages
AT nakaichimunekazu outcomesofmegavoltageradiotherapyforcanineintranasaltumorsanditsrelationshiptoclinicalstages